SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-008588
Filing Date
2022-02-22
Accepted
2022-02-22 08:01:29
Documents
3
Period of Report
2022-02-22

Document Format Files

Seq Description Document Type Size
1 FORM 6-K ea155963-6k_enlivex.htm 6-K 10188
2 PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON FEBRUARY 22, 2022. ea155963ex99-1_enlivex.htm EX-99.1 10410
3 GRAPHIC image_001.jpg GRAPHIC 3194
  Complete submission text file 0001213900-22-008588.txt   26376
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 22655069
SIC: 2834 Pharmaceutical Preparations